Search Results - "Lee, Li‐Po"

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial by Yu, Ming‐Lung, Dai, Chia‐Yen, Huang, Jee‐Fu, Chiu, Chang‐Fu, Yang, Yi‐Hsin C., Hou, Nai‐Jen, Lee, Li‐Po, Hsieh, Ming‐Yen, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Hsieh, Ming‐Yuh, Wang, Liang‐Yen, Chang, Wen‐Yu, Chuang, Wan‐Long

“…Recommended treatment for hepatitis C virus genotype 1 (HCV‐1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of…”
Get full text

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C by Yu, Ming-Lung, Dai, Chia-Yen, Huang, Jee-Fu, Hou, Nai-Jen, Lee, Li-Po, Hsieh, Ming-Yen, Chiu, Chang-Fu, Lin, Zu-Yau, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Chang, Wen-Yu, Chuang, Wan-Long

“…Background: The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for…”
Get full text

Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study by Dai, Chia-Yen, Chuang, Wan-Long, Ho, Chi-Kung, Hsieh, Ming-Yen, Huang, Jee-Fu, Lee, Li-Po, Hou, Nai-Jen, Lin, Zu-Yau, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Tsai, Jun-Fa, Chang, Wen-Yu, Yu, Ming-Lung

“…Background/Aims To evaluate the association of virologic status with serum cholesterol and triglyceride levels in individuals with hepatitis C virus (HCV)…”
Get full text

Viral Hepatitis Infections in Southern Taiwan: A Multicenter Community-based Study by Yang, Jeng-Fu, Lin, Chia-I, Huang, Jee-Fu, Dai, Chia-Yen, Lin, Wen-Yi, Ho, Chi-Kung, Hsieh, Ming-Yen, Lee, Li-Po, Ho, Nai-Jen, Lin, Zu-Yau, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Yu, Ming-Lung, Chuang, Wan-Long, Chang, Wen-Yu

“…Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of liver disease in Taiwan and have a great impact on the health of this…”
Get full text

A simple noninvasive index for predicting long‐term outcome of chronic hepatitis C after interferon‐based therapy by Yu, Ming‐Lung, Lin, Shi‐Ming, Lee, Chuan‐Mo, Dai, Chia‐Yen, Chang, Wen‐Yu, Chen, Shinn‐Cherng, Lee, Li‐Po, Lin, Zu‐Yau, Hsieh, Ming‐Yuh, Wang, Liang‐Yen, Chuang, Wan‐Long, Liaw, Yun‐Fan

“…Changes in hepatic fibrosis after interferon‐based therapy may be important in determining the long‐term outcome of chronic hepatitis C (CHC). The use of liver…”
Get full text

The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies by Huang, Jee-Fu, Hsieh, Ming-Yen, Dai, Chia-Yen, Hou, Nai-Jen, Lee, Li-Po, Lin, Zu-Yau, Chen, Shinn-Chern, Wang, Liang-Yen, Hsieh, Ming-Yuh, Chang, Wen-Yu, Yu, Ming-Lung, Chuang, Wan-Long

“…The reasons for the liver biopsy studies on these patients, were either a result of chronic viral hepatitis or a surveillance of abnormal liver function tests…”
Get full text

Tumor Necrosis Factor–α Promoter Polymorphism at Position −308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection by Dai, Chia-Yen, Chuang, Wan-Long, Chang, Wen-Yu, Chen, Shinn-Cherng, Lee, Li-Po, Hsieh, Ming-Yen, Hou, Nai-Jen, Lin, Zu-Yau, Huang, Jee-Fu, Hsieh, Ming-Yuh, Wang, Liang-Yen, Yu, Ming-Lung

“…The G→A transition in the tumor necrosis factor (TNF)–α promoter region at position −308 (TNF308.2) and −238 (TNF238.2) were determined in 141 patients with…”
Get full text

Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients by Lee, Li-Po, Dai, Chia-Yen, Chuang, Wan-Long, Chang, Wen-Yu, Hou, Nei-Jen, Hsieh, Ming-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Chen, Tong-Jong, Yu, Ming-Lung

“…Background:  The aim of the present study was to compare the histological characteristics of livers between chronic hepatitis C (CHC) patients with and without…”
Get full text

A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan by Yu, Ming-Lung, Dai, Chia-Yen, Lin, Zu-Yau, Lee, Li-Po, Hou, Nei-Jen, Hsieh, Ming-Yen, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Chang, Wen-Yu, Chuang, Wan-Long

“…: Background: To assess the efficacy of 24‐ or 48‐week peginterferon/ribavirin treatment of Taiwanese patients with chronic hepatitis C virus genotype‐1b…”
Get full text

Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients by Hsieh, Ming-Yen, Dai, Chia-Yen, Lee, Li-Po, Huang, Jee-Fu, Chuang, Wan-Long, Hou, Nai-Jen, Lin, Zu-Yau, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Chang, Wen-Yu, Yu, Ming-Lung

“…Abstract Positive serum antinuclear antibody (ANA) is not infrequent in chronic hepatitis C virus (HCV)-infected patients. This prospective study evaluated the…”
Get full text

Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan by Hsieh, Meng-Hsuan, Lee, Li-Po, Hsieh, Ming-Yen, Tsai, Kun-Bow, Huang, Jee-Fu, Hou, Nai-Jen, Chen, Shinn-Chern, Lin, Zu-Yau, Hsieh, Ming-Yuh, Wang, Liang-Yen, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung

“…Hepatitis C virus (HCV) infection has been associated with hepatic steatosis. However, the role of hepatic steatosis in the pathogenesis of HCV infection…”
Get full text

Links between triglyceride levels, hepatitis C virus infection and diabetes by Dai, Chia-Yen, Huang, Jee-Fu, Hsieh, Ming-Yen, Lee, Li-Po, Hou, Nai-Jen, Yu, Ming-Lung, Chuang, Wan-Long

“…Table 1 Comparison of factors in subjects with and without diabetes and subjects with and without abnormal triglyceride levels among 642 anti-HCV-positive…”
Get full text

The role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and C by Dai, Chia-Yen, Huang, Jee-Fu, Hsieh, Ming-Yen, Lee, Li-Po, Ho, Chi-Kung, Chuang, Wan-Long, Yu, Ming-Lung

“…Table 1 Comparison of clinical factors between 642 anti-hepatitis C virus (HCV)-positive participants with and without clearance of serum HCV RNA Clinical…”
Get full text

Human Leukocyte Antigen Class I and II Alleles and Response to Interferon-α Treatment, in Taiwanese Patients with Chronic Hepatitis C Virus Infection by Yu, Ming-Lung, Dai, Chia-Yen, Chen, Shinn-Cherng, Chiu, Chao-Chin, Lee, Li-Po, Lin, Zu-Yau, Hsieh, Ming-Yuh, Wang, Liang-Yen, Chuang, Wan-Long, Chang, Wen-Yu

“…To investigate the influence of immunogenetics on response to interferon (IFN)-α treatment, human leukocyte antigen alleles were characterized in 100 unrelated…”
Get full text

A 24-week course of high-dose interferon-α plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels by Yu, Ming-Lung, Dai, Chia-Yen, Lee, Li-Po, Hou, Nei-Jen, Hsieh, Ming-Yen, Huang, Jee-Fu, Lin, Zu-Yau, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Chang, Wen-Yu, Chuang, Wan-Long

“…: Background/Aims: We aimed to evaluate the efficacy, advantage, and safety of a 24‐week regimen with high‐dose interferon‐α (INF‐α; 6 million units thrice…”
Get full text

Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin by Dai, Chia-Yen, Chuang, Wan-Long, Chang, Wen-Yu, Chen, Shinn-Cherng, Lee, Li-Po, Hsieh, Ming-Yen, Hou, Nei-Jen, Lin, Zu-Yau, Hsieh, Ming-Yuh, Wang, Liang-Yen, Yu, Ming-Lung

“…AIM： The clinical significance of co-infection of SENV-D among patients with chronic hepatitis C （CHC） and response of both viruses to combination therapy with…”
Get full text

Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication by HUANG, Jee-Fu, DAI, Chia-Yen, WANG, Liang-Yen, SHIN, Shyi-Jang, CHANG, Wen-Yu, CHUANG, Wan-Long, YU, Ming-Lung, HWANG, Shang-Jyh, HO, Chi-Kung, HSIAO, Pi-Jung, HSIEH, Ming-Yen, LEE, Li-Po, LIN, Zu-Yau, CHEN, Shinn-Chern, HSIEH, Ming-Yuh

“…There is growing evidence with regard to the association between hepatitis C virus (HCV) infection and type 2 diabetes mellitus (T2DM). However, the mutual…”
Get full text

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study by Yu, Ming-Lung, Dai, Chia-Yen, Chen, Shinn-Cherng, Lee, Li-Po, Hsieh, Ming-Yen, Lin, Zu-Yau, Hsieh, Ming-Yuh, Wang, Liang-Yen, Tsai, Jung-Fa, Chang, Wen-Yu, Chuang, Wan-Long

“…Interferon-alpha monotherapy is effective in less than one-third patients with chronic hepatitis C. The dose-effect, tolerability and durability of…”
Get full text

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-α monotherapy in Taiwan by Chuang, Wan-Long, Dai, Chia-Yen, Chen, Shinn-Cherng, Lee, Li-Po, Lin, Zu-Yau, Hsieh, Ming-Yuh, Wang, Liang-Yen, Yu, Ming-Lung, Chang, Wen-Yu

“…: With the favorable result of interferon (IFN)–ribavirin combination therapy for 24 weeks among naive Taiwanese chronic hepatitis C (CHC) patients, the…”
Get full text

Qualitative Application of COBAS AMPLICOR HCV Test Version 2.0 Assays in Patients with Chronic Hepatitis C Virus Infection and Comparison of Clinical Performance with Version 1.0 by Hsieh, Ming-Yen, Lee, Li-Po, Hou, Nai-Jen, Yang, Jeng-Fu, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Lin, Zu-Yau, Chen, Shinn-Cherng, Hsieh, Ming-Yuh, Wang, Liang-Yen, Chang, Wen-Yu, Yu, Ming-Lung

“…The objective of this research was to investigate the clinical performance of COBAS AMPLICOR hepatitis C virus (HCV) test version 2.0 Assays (CA V2.0). Eight…”
Get full text